FOLH1 and prostate carcinoma: The radiometal gallium-68 (68Ga) PET has garnered much attention in recent years, particularly following FDA approval of two 68Ga agents (68Ga-DOTATATE (DOTA-0-Tyr3-Octreotate) and 68Ga-DOTATOC (DOTA0-Phe1-Tyr3)octreotide)) and the success of 68Ga-agents targeting prostate-specific membrane antigen (PSMA) in prostate cancer clinical studies.